Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

This study has been completed.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Nagehan Kucukler, Mustafa Kemal University Identifier:
First received: August 18, 2011
Last updated: August 29, 2011
Last verified: August 2011
The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.

Condition Intervention Phase
Left Ventricular Hypertrophy
Drug: valsartan
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

Resource links provided by NLM:

Further study details as provided by Mustafa Kemal University:

Primary Outcome Measures:
  • change from baseline in midwall fractional shortening (mFS) and tissue Doppler systolic wave (Sm) measured by echocardiography at six months [ Time Frame: six months ]

Secondary Outcome Measures:
  • change from baseline in systolic and diastolic blood pressure at six months [ Time Frame: six months ]
  • change from baseline in left ventricular mass index measured by echocardiography at six months [ Time Frame: six months ]

Enrollment: 38
Study Start Date: November 2006
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Valsartan treatment Drug: valsartan
80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
Other Names:
  • Diovan 80 mg
  • Diovan 160 mg
  • Co-diovan 160/12,5 mg


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hypertension with left ventricular hypertrophy

Exclusion Criteria:

  • clinical or laboratory evidence of secondary hypertension
  • heart failure
  • ischemic heart disease
  • valvular heart disease
  • arrhythmias
  • peripheral vascular disease
  • chronic obstructive pulmonary disease
  • neurologic disorders
  • diabetes mellitus
  • renal dysfunction
  • notable systemic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01425411

Mustafa Kemal University School of Medicine, Department of Cardiology
Antioch, Turkey, 31100
Sponsors and Collaborators
Mustafa Kemal University
Novartis Pharmaceuticals
Principal Investigator: Fatih Yalcin, M.D. Mustafa Kemal University: Turkey
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nagehan Kucukler, MD, Mustafa Kemal University Identifier: NCT01425411     History of Changes
Other Study ID Numbers: vals262626
Study First Received: August 18, 2011
Last Updated: August 29, 2011

Keywords provided by Mustafa Kemal University:
left ventricular hypertrophy
angiotensin receptor blocker
midwall mechanics
tissue Doppler imaging
Hypertension with left ventricular hypertrophy

Additional relevant MeSH terms:
Hypertrophy, Left Ventricular
Vascular Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical
Heart Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on April 25, 2017